Status:
COMPLETED
Local Hyperthermia for the Treatment of Cervical Intraepithelial Neoplasias
Lead Sponsor:
First Hospital of China Medical University
Conditions:
Cervical Intraepithelial Neoplasia
Human Papilloma Virus
Eligibility:
FEMALE
18-65 years
Phase:
NA
Brief Summary
Human papillomavirus(HPV) infect epithelial cells and have the capacity to stimulate cell abnormal hyperplasia, especially by those high-risk HPV types. HPV vaccine primarily targeting HPV6/11/16/18 h...
Detailed Description
Mild local Hyperthermia with a certain temperature range has been successfully used in the treatment of some diseases. It has been utilised in the treatment of some neoplasm, fungal and HPV infections...
Eligibility Criteria
Inclusion
- 18-65 years old; generally healthy gynecological conditions, normal sexual life; high risk HPV; Cervical biopsy CIN or no cytological changes; signed informed consent
Exclusion
- Pregnant woman;local or systematic treatment within 3 months; Comorbidity of other severe gynecological inflammation, infection, or tumor; Comorbidity of other serious illnesses； no guarantee of timely treatment and follow-up
Key Trial Info
Start Date :
January 28 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2020
Estimated Enrollment :
53 Patients enrolled
Trial Details
Trial ID
NCT03436251
Start Date
January 28 2018
End Date
August 1 2020
Last Update
August 18 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Yang Yang
Shenyang, Liaoning, China, 110001